2018 Raynaud's Syndrome Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Raynaud's Syndrome Market
Raynaud's syndrome refers to a vascular condition that affects the blood flow to small tissues such as the ones in hands and toes. Around 20 to 25 million people are affected by Raynaud's syndrome in the US.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Raynaud's Syndrome pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Raynaud's Syndrome pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Raynaud's Syndrome pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Raynaud's Syndrome pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Raynaud's Syndrome pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Raynaud's Syndrome pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 RAYNAUD'S SYNDROME PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Raynaud's Syndrome Pipeline Snapshot
2.3 Raynaud's Syndrome Pipeline by Phase
2.4 Raynaud's Syndrome Pipeline by Company
2.5 Raynaud's Syndrome Pipeline by Mechanism of Action
3 RAYNAUD'S SYNDROME- COMPANY WISE PIPELINE ANALYSIS
Allergan Plc
Apricus Biosciences, Inc.
Bayer AG
Exodos Life Sciences Limited Partnership
Pfizer Inc.
4 RAYNAUD'S SYNDROME R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN RAYNAUD'S SYNDROME PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 RAYNAUD'S SYNDROME PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Raynaud's Syndrome Pipeline Snapshot
2.3 Raynaud's Syndrome Pipeline by Phase
2.4 Raynaud's Syndrome Pipeline by Company
2.5 Raynaud's Syndrome Pipeline by Mechanism of Action
3 RAYNAUD'S SYNDROME- COMPANY WISE PIPELINE ANALYSIS
Allergan Plc
Apricus Biosciences, Inc.
Bayer AG
Exodos Life Sciences Limited Partnership
Pfizer Inc.
4 RAYNAUD'S SYNDROME R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN RAYNAUD'S SYNDROME PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Raynaud's Syndrome Pipeline by Phase, H2- 2018
Figure 2: Raynaud's Syndrome Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Raynaud's Syndrome Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Raynaud's Syndrome Pipeline by Phase, H2- 2018
Figure 2: Raynaud's Syndrome Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Raynaud's Syndrome Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Raynaud's Syndrome Pipeline by Phase, H2- 2018
Raynaud's Syndrome Pipeline by Companies, H2- 2018
Raynaud's Syndrome Pipeline by Mechanism of Action, H2- 2018
Table 1: Allergan Plc Raynaud's Syndrome Pipeline Drugs, H2- 2018
Table 2: Apricus Biosciences, Inc. Raynaud's Syndrome Pipeline Drugs, H2- 2018
Table 3: Bayer AG Raynaud's Syndrome Pipeline Drugs, H2- 2018
Table 4: Exodos Life Sciences Limited Partnership Raynaud's Syndrome Pipeline Drugs, H2- 2018
Table 5: Pfizer Inc. Raynaud's Syndrome Pipeline Drugs, H2- 2018
Raynaud's Syndrome Pipeline by Phase, H2- 2018
Raynaud's Syndrome Pipeline by Companies, H2- 2018
Raynaud's Syndrome Pipeline by Mechanism of Action, H2- 2018
Table 1: Allergan Plc Raynaud's Syndrome Pipeline Drugs, H2- 2018
Table 2: Apricus Biosciences, Inc. Raynaud's Syndrome Pipeline Drugs, H2- 2018
Table 3: Bayer AG Raynaud's Syndrome Pipeline Drugs, H2- 2018
Table 4: Exodos Life Sciences Limited Partnership Raynaud's Syndrome Pipeline Drugs, H2- 2018
Table 5: Pfizer Inc. Raynaud's Syndrome Pipeline Drugs, H2- 2018
